Immunogenicity and reactogenicity of a third dose of bnt162b2 vaccine for covid-19 after a primary regimen with bbibp-corv or bnt162b2 vaccines in lima, peru

HIGHLIGHTS

SUMMARY

In May 2021, vaccination started on people 60 years and older with the BNT162b2 (Pfizer-BioNTech) mRNA_vaccine, and subsequently the vaccination program was extended to the younger population according to vaccine availability, using mainly BBIBP-CorV and ChAdOx1 nCoV-19 (Oxford-AstraZeneca) in under 40s. The population comprised two groups: People initially vaccinated with 2 doses of BNT162b2 (Pfizer-Biotech), mainly individuals aged 60 years and older; and people vaccinated with 2 doses of BBIBP-CorV (Sinopharm), mostly HCWs of any profession. Sampling was carried out in a consecutive non-probabilistic manner in four . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or Email

Password

Remember me

Lost your password?

If you don't have an account, you can create one here.